On June 10, 2025, Iovance Biotherapeutics, Inc. held its Annual Meeting where stockholders voted on five proposals, including the election of new board members and compensation approvals, with 76.1% of shares represented. Notably, all proposals passed with significant voter support, including an increase of 12.5 million shares in the 2018 Equity Incentive Plan.